Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
bioMérieux S.A. (BIM.PA)
EUR71.85
+1.65 (+2.35%)
FR PAR Healthcare Medical - Diagnostics & Research
Address
376 Chemin De l'Orme 69280
Marcy l'Étoile, FR
Marcy l'Étoile, FR
CEO
Pierre Boulud
Website
biomerieux.com
IPO
2004-07-07
ISIN FR0013280286
Also trades on
Euronext Paris · BIM.PA (EUR)
Other OTC · BMXMF (USD)
Other OTC · BMXXY (USD)
Description
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR71.85
+1.65 (+2.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
207.6K
Beta
0.57
Float Shares
41.31M
Free Float %
35.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.50% | +0.54% | +3.70% | -25.65% | -31.09% | -32.59% | -37.04% | -21.97% | -20.92% | +90.64% | +13,754.21% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
71.85
DCF (Unlevered)
153.31
+113.4%
DCF (Levered)
80.98
+12.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
31% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | -1 |
| Hold | 9 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.93
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+2.3% Q4'25: +6.4% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%-8.2% Q4'25: +20.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+11.4% Q4'25: +14.2% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+13.8% ★ Q4'25: +8.8% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%+10.6% ★ Q4'25: +13.5% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.2% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.46× Q4'25: 0.24× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 10 EPS Ana. |
Dec 2027 11 Rev. Ana. 10 EPS Ana. |
Dec 2028 9 Rev. Ana. 8 EPS Ana. |
Dec 2029 4 Rev. Ana. 6 EPS Ana. |
Dec 2030 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.43B
est: 1.45B (-1.4%)
|
1.57B
est: 1.59B (-1.1%)
|
1.59B
est: 1.62B (-1.8%)
|
1.70B
est: 1.71B (-0.5%)
|
1.96B
est: 1.96B (+0.0%)
|
2.10B
est: 2.10B (+0.0%)
|
2.29B
est: 2.29B (+0.0%)
|
2.42B
est: 2.41B (+0.5%)
|
2.67B
est: 2.64B (+1.2%)
|
3.12B
est: 3.13B (-0.3%)
|
3.38B
est: 3.33B (+1.3%)
|
3.59B
est: 3.55B (+1.2%)
|
3.67B
est: 3.81B (-3.5%)
|
3.98B
est: 3.95B (+0.9%)
|
4.07B
est: 4.08B (-0.4%)
|
4.15B
3.96B – 4.28B
+1.6% YoY
|
4.43B
4.22B – 4.64B
+6.7% YoY
|
4.76B
4.74B – 4.77B
+7.5% YoY
|
4.94B
4.71B – 5.14B
+3.8% YoY
|
5.20B
4.95B – 5.41B
+5.2% YoY
|
| EBITDA |
327.10M
est: 345.48M (-5.3%)
|
322.70M
est: 350.02M (-7.8%)
|
344.40M
est: 322.63M (+6.7%)
|
307.50M
est: 336.97M (-8.7%)
|
383.90M
est: 317.61M (+20.9%)
|
416.90M
est: 293.24M (+42.2%)
|
445.50M
est: 414.27M (+7.5%)
|
508.90M
est: 429.66M (+18.4%)
|
548.20M
est: 516.17M (+6.2%)
|
747.70M
est: 596.06M (+25.4%)
|
977.80M
est: 636.27M (+53.7%)
|
811.90M
est: 680.23M (+19.4%)
|
701.30M
est: 896.66M (-21.8%)
|
897.50M
est: 926.28M (-3.1%)
|
999.60M
est: 962.17M (+3.9%)
|
977.23M
932.40M – 1.01B
+1.6% YoY
|
1.04B
993.04M – 1.09B
+6.7% YoY
|
1.12B
1.12B – 1.12B
+7.5% YoY
|
1.16B
1.11B – 1.21B
+3.8% YoY
|
1.22B
1.17B – 1.27B
+5.2% YoY
|
| EBIT |
241.80M
est: 259.22M (-6.7%)
|
228.30M
est: 268.67M (-15.0%)
|
247.80M
est: 243.16M (+1.9%)
|
202.10M
est: 268.02M (-24.6%)
|
193.90M
est: 235.24M (-17.6%)
|
255.00M
est: 216.55M (+17.8%)
|
286.70M
est: 307.65M (-6.8%)
|
316.00M
est: 329.71M (-4.2%)
|
340.70M
est: 380.83M (-10.5%)
|
519.30M
est: 427.89M (+21.4%)
|
757.40M
est: 456.75M (+65.8%)
|
554.30M
est: 488.30M (+13.5%)
|
441.90M
est: 598.72M (-26.2%)
|
595.30M
est: 618.51M (-3.8%)
|
561.20M
est: 642.47M (-12.6%)
|
652.52M
622.59M – 672.76M
+1.6% YoY
|
696.56M
663.08M – 730.61M
+6.7% YoY
|
748.60M
746.21M – 750.99M
+7.5% YoY
|
777.17M
740.64M – 808.44M
+3.8% YoY
|
817.37M
778.95M – 850.25M
+5.2% YoY
|
| Net Income |
158.20M
est: 168.60M (-6.2%)
|
134.40M
est: 173.20M (-22.4%)
|
164.30M
est: 139.07M (+18.1%)
|
134.90M
est: 172.69M (-21.9%)
|
110.50M
est: 155.86M (-29.1%)
|
179.10M
est: 119.56M (+49.8%)
|
238.10M
est: 195.77M (+21.6%)
|
256.60M
est: 249.56M (+2.8%)
|
272.80M
est: 279.16M (-2.3%)
|
404.40M
est: 315.00M (+28.4%)
|
601.10M
est: 336.25M (+78.8%)
|
452.40M
est: 385.90M (+17.2%)
|
357.60M
est: 411.30M (-13.1%)
|
432.20M
est: 482.11M (-10.4%)
|
397.50M
est: 543.85M (-26.9%)
|
505.96M
496.72M – 587.62M
-7.0% YoY
|
561.07M
543.19M – 681.75M
+10.9% YoY
|
631.83M
605.95M – 762.68M
+12.6% YoY
|
725.97M
681.62M – 763.94M
+14.9% YoY
|
749.10M
703.33M – 788.28M
+3.2% YoY
|
| SGA |
372.10M
est: 363.33M (+2.4%)
|
409.00M
est: 407.39M (+0.4%)
|
404.60M
est: 423.21M (-4.4%)
|
453.00M
est: 425.26M (+6.5%)
|
529.20M
est: 523.39M (+1.1%)
|
569.50M
est: 571.57M (-0.4%)
|
603.90M
est: 622.17M (-2.9%)
|
643.10M
est: 632.70M (+1.6%)
|
749.80M
est: 707.63M (+6.0%)
|
789.30M
est: 865.47M (-8.8%)
|
815.60M
est: 923.85M (-11.7%)
|
954.70M
est: 987.67M (-3.3%)
|
1.02B
est: 1.02B (+0.5%)
|
1.10B
est: 1.05B (+4.6%)
|
1.11B
est: 1.09B (+2.0%)
|
1.11B
1.06B – 1.14B
+1.6% YoY
|
1.18B
1.12B – 1.24B
+6.7% YoY
|
1.27B
1.27B – 1.27B
+7.5% YoY
|
1.32B
1.26B – 1.37B
+3.8% YoY
|
1.39B
1.32B – 1.44B
+5.2% YoY
|
| EPS |
1.34
est: 1.40 (-4.2%)
|
1.14
est: 1.45 (-21.4%)
|
1.39
est: 1.40 (-0.8%)
|
1.14
est: 1.19 (-3.9%)
|
0.93
est: 1.32 (-29.8%)
|
1.51
est: 1.52 (-0.6%)
|
2.02
est: 1.86 (+8.8%)
|
2.18
est: 2.06 (+5.8%)
|
2.31
est: 2.36 (-2.2%)
|
3.42
est: 3.54 (-3.3%)
|
5.08
est: 4.66 (+8.9%)
|
3.84
est: 4.07 (-5.6%)
|
3.03
est: 3.49 (-13.1%)
|
3.67
est: 4.07 (-9.8%)
|
3.37
est: 4.59 (-26.5%)
|
4.50
4.17 – 4.94
-1.9% YoY
|
5.02
4.56 – 5.73
+11.5% YoY
|
5.67
5.09 – 6.41
+12.9% YoY
|
6.10
5.73 – 6.42
+7.7% YoY
|
6.29
5.91 – 6.62
+3.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.08B
OE per share TTM
9.07
Owner's Yield
12.32%
Maintenance CapEx ratio
57.24%
Maint CapEx / Avg PPE
39.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 271 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares EURO STOXX Small UCITS ETF DJSC.L | 1.18% | 5.76M | 0.40% |
| 2 | iShares STOXX Europe Small 200 UCITS ETF (DE) EXSE.DE | 0.52% | 3.52M | 0.20% |
| 3 | WisdomTree International Multifactor Fund DWMF | 0.44% | 149.2K | 0.38% |
| 4 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.44% | 5.02M | 0.40% |
| 5 | iShares MSCI Europe Mid-Cap Equal Weight UCITS ETF IEFS.L | 0.43% | 167.2K | 0.25% |
| 6 | iShares Edge MSCI Europe Minimum Volatility UCITS ETF IMVU.L | 0.33% | 3.30M | 0.25% |
| 7 | iShares Edge MSCI Europe Minimum Volatility UCITS ETF MVED.L | 0.33% | 92.7K | 0.25% |
| 8 | Amundi CAC Transition Climat UCITS ETF CF1.PA | 0.27% | 36.0K | 0.25% |
| 9 | Invesco STOXX Europe 600 Optimised Health Care UCITS ETF SC0T.DE | 0.26% | 34.7K | 0.20% |
| 10 | iShares MSCI EMU Mid Cap UCITS ETF EUR EMUM.L | 0.24% | 1.46M | 0.49% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
39.7K
Shares Outstanding
117.99M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pierre Boulud | Chief Executive Officer | 2M | male |
| Frederic Beseme | Head of CSR | 22.0K | male |
| Charles K. Cooper | Executive VP of Medical Affairs & Chief Medical Officer | — | — |
| Guillaume Bouhours | Executive VP of Finance, Purchasing and Information Systems & CFO | — | male |
| Jennifer Zinn | Executive Vice President of Clinical Operations | — | female |
| Pierre Charbonnier | Executive Vice President of Global Quality, Manufacturing & Supply Chain | — | male |
| Valerie Leylde | Executive Vice President of Human Resources, Communications & CSR | — | female |
| Audrey Dauvet | Executive Vice President of Legal, Corporate Integrity & Public Affairs | — | female |
| Yasha Mitrotti | Executive Vice President of Industrial Applications | — | male |
| Celine Roger-Dalbert | Executive Vice President of Research & Development | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIM.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
